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Summary MDM2 is an oncoprotein that inhibits p53 tumour-suppressor protein. Amplification of the MDM2 gene and overexpression of its
protein have been observed in some human malignancies, and these abnormalities have a role in tumorigenesis through inactivation of p53
function. To determine the clinicopathological and prognostic value of MDM2 abnormalities in non-small-cell lung cancer (NSCLC), MDM2
gene amplification and its protein expression status were analysed in surgically resected materials. MDM2gene amplification was detected in
only 2 (7%) of the 30 tested patients. MDM2 protein was found immunohistochemically in a total of 48 (24%) of the 201 patients. MDM2
protein was slightly frequently observed in patients with adenocarcinoma, but its presence or absence was not associated with
clinicopathological factors such as T-factor, N-factor, stage, tumour size, differentiation or p53 protein status. Overall, MDM2-positive patients
tended to have a better prognosis (P = 0.062). In particular, among immunohistochemically p53-negative patients (n = 110), those with
positive MDM2 protein expression showed significantly better prognosis (P = 0.039) and, in a multivariate analysis, MDM2 protein status was
a favourable prognostic factor (P = 0.037). In contrast, among p53-positive patients (n = 91), there was no difference in prognosis depending
on MDM2 protein status. Thus, in the NSCLC patients studied, MDM2 gene amplification was a minor event, but expression of its protein,
which was often observed immunohistochemically, was a favourable prognostic marker, especially among patients without p53 protein
accumulation. Further study is needed to determine how MDM2 protein expression results in a better prognosis.
Keywords: MDM2 gene; non-small-cell lung cancer; p53; prognosis; immunohistochemistry; amplification; fluorescence-based polymerase
chain reaction single-strand conformation polymorphism
The MDM2 gene was originally identified and cloned by amplifi-
cation in a transformed tumorigenic Balb/c 3T3 fibroblast cell line
(Cahilly-Snyder et al, 1987; Fakharzadeh et al, 1991; Oliner et al,
1992). Its product, p90, is now considered to form a tight complex
with both the wild-type and mutant p53 tumour-suppressor gene
protein and to inactivate wild-type p53 function by masking the N-
terminal acidic transactivating domain of p53 protein, indicating
that abnormalities of the MDM2 gene may be closely associated
with tumorigenesis and/or tumour development (Olson et al, 1993;
Haines et al, 1994). Indeed, MDM2 gene amplification and over-
expression of its product have been described in several types of
malignancies in humans. However, the clinicopathological role of
these abnormalities has yet to be determined.
In lung cancer, p53 abnormalities have been well examined but,
to our knowledge, MDM2 abnormalities in this disease have been
reported only by Marchetti et al (1995a). However, because ofthe
relatively small number of samples tested in their study, its clini-
copathological and prognostic significance is as yet unknown.
Hence, because p53 abnormalities in this disease may be essential
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for biological and clinical characteristics of the tumour, we exam-
ined MDM2 abnormality status, especially in those patients
without p53 abnormalities. MDM2 gene amplification and its
protein expression were examined in a series ofsurgically resected
non-small-cell lung cancer (NSCLC) cases in association with




For immunohistochemical analysis of MDM2 protein expression
and p53 accumulation, formalin-fixed paraffin-embedded tissue
blocks ofprimary tumours removed surgically between July 1989
and June 1995 at the Department of Thoracic Surgery, Osaka
Medical Center for Cancer and Cardiovascular Diseases (formerly
the Center for Adult Diseases, Osaka), were obtained from 201
NSCLC patients. For amplification analysis of the MDM2 gene,
30 fresh tissue samples were immediately frozen at the time ofthe
operation and stored at-80°C until DNA extraction.
Of the 201 patients, 146 were men and 48 were women; they
were aged between 35 and 83 years (mean 63.4 years). The histo-
logical type was adenocarcinoma in 116 patients, squamous cell
carcinoma in 71, large-cell carcinoma in 12 and adenosquamous
cell carcinoma in two. The pathological staging was according to
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Figure 1 Immunostaining of strongly positive MDM2 protein expression in NSCLC (++). Almost all nuclei of cancer cells (percentage of positive cells: A, 75%;
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Figure 2 Amplification of MDM2 gene in NSCLCs. (A) Southern blot
hybridization with the MDM2 probe. (B) Southern blot hybridization with the
pYNH132 probe for internal control. MDM2 gene amplification was observed
in case no. 24 (lane 1) and case no. 3 (lane 4)
the international TNM staging system (Mountain, 1986): stage I in
115, stage II in 23, stage IIIA in 57 and stage IIIB in six. All
patients underwent potentially curative operations. The median
post-operative follow-up of the patients was 839 days (range
32-2469 days). Post-operative survival curves were constructed
using the Kaplan-Meier method.
MDM2amplification and p53 mutation analysis
Southern blot analysis was performed to detect amplification of
the MDM2 gene, as described previously (Takami et al, 1994). The
human MDM2 cDNA clone (c14-2; nt 1-949), which was kindly
provided by Drs B Vogelstein and KW Kinzler, was used as a
hybridization probe. pYNH132 on chromosome 6p, pLYNZ9. 1 on
chromosome 2p and pMCAI -I on chromosome 15q were used as
internal diploid standards (kindly provided by Dr Y Nakamura).
Briefly, 5 .tg of high molecular weight DNA derived from tumour
tissues was digested with EcoR I and then electrophoresed on
0.8% agarose gel followed by transfer to a nylon filter. The DNAs
on the filters were sequentially hybridized with the MDM2 gene
probe, c14-2, and three control probes, pYNH132, pLYNZ9. 1 and
pMCAI-1. The intensity of the hybridization signals was
measured by densitometry. The relative signal intensities of the
MDM2 gene were calculated by comparing the ratio of MDM2 to
three control probes and, when the samples showed a more than
two fold increase in signal intensity of MDM2, they were
hybridized with two probes, pYNH15 on chromosome 12q and
pHua2M9 on chromosome 12p, to determine whether or not the
increase was due to non-specific polysomies ofthe chromosome.
Mutations of the p53 gene were examined using fluorescence-
based polymerase chain reaction single-strand conformation poly-
morphism (PCR-FSSCP), as described previously by Katsuragi et
al (1995). This technique was used for the detection ofpoint muta-
tions in thep53 gene in exons 5, 6, 7 and 8 by an automated DNA
sequencer and software.
Immunohistochemical analysis
Sections were cut at 4 ,um, dewaxed and rehydrated through a
graded ethanol series. Before staining, sections were pretreated
with microwave irradiation forantigen retrieval, as described previ-
ously (Cattoretti et al, 1992; Marchetti et al, 1995b; McCann et al,
1995; Ofner et al, 1995). Incubation with the primary antibodies
(monoclonal MDM2 antibody, IF-2, Oncogene Science, USA, and
monoclonal p53 antibody, DO-7, Novocastra Laboratories, UK),
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Table 1 MDM2 and p53 abnormalities in NSCLC
No. Histology stage MDM2 p53
Amplification Protein Mutation Protein
1 Ad IIIB - - - +
2 Ad IIIB - - NT ++
3 Ad IIIA +(5.5-fold) ++ - ++
4 Ad IIIA - + NT -
5 Ad IIIA - ++ +(Exon6) ++
6 Ad IIIA - - NT -
7 Ad IIIA - - NT -
8 Ad IIIA - - NT -
9 Ad I - + +
10 Ad I I - NT ++
11 AdIl - NT ++
12 Ad I - + - -
13 Ad I - - - ++
14 Ad I - + - -
15 Ad I - + - -
16 Ad - - - -
17 Ad I - - - +
18 Ad - - NT -
19 Sq IIIB - - - ++
20 Sq IIIA - + +(Exon8) +
21 Sq IIIA - - NT ++
22 Sq IIIA - NT -
23 Sq II - + +(Exon5) ++
24 Sq +(2.7-fold) + - ++
25 Sq - +(Exon7) +
26 Sq - NT +
27 Sq - + NT -
28 Sql - - NT +
29 La IIIA - + NT ++
30 La - - NT -
Positive patients/tested patients 2/30 12/30 4/15 18/30
(7%) (40%) (27%) (60%)
Ad, adenocarcinoma; Sq, squamous cell carcinoma; La, large-cell carcinoma;
NT, not tested.
the enzyme colour reaction, haematoxylin counterstaining and
mounting were carried out as described elsewhere (Foulkes et al,
1995; Marchetti et al, 1995a and b; McCann etal, 1995; Ofneret al,
1995; Matsumura et al, 1996).
Immunostaining results were assessed, taking into account the
cancer cells whose nuclei showed positive immunoreactivity for
MDM2 (Figure 1) or p53 protein. The percentage ofimmunoreac-
tive nuclei was evaluated by scanning the whole section at medium
and high magnification and by counting at least 500 cells in the
most densely stained tumour areas. The patients were classified
into three groups: a strongly positive group (++), with more than
50% positive cancer cells in the tissue; aweakly positive group (+),
with 10-50% positive cancer cells; and a negative group (-) with
less than 10% or no positive cancer cells (McCann et al, 1995).
Statistical analysis
The chi-square test was applied for statistical analysis. For
survival data, statistical significance was analysed using the log-
rank test. Variables related to survival were analysed using Cox's
proportional hazards regression model with SAS software
(Statistical Analysis Institute, Cary, NC, USA). P < 0.05 was
considered to be significant and 0.05 < P < 0.10 was considered to
be marginally significant.
Table 2 Relationship between MDM2 oncoprotein and clinicopathological
parameters in 201 NSCLC patients undergoing potentially curative operation
MDM2 protein status P-value
_+ ++
(n = 153) (n =38) (n =10)
76% 19% 5%
Gender
Male 117 24 5
Female 36 14 5 0.07
Age (mean year) 63.2 65.0 61.2 NS
T-factor
Ti 42 13 5
T2 80 19 4
T3,4 31 6 1 NS
N-factor
NO 103 27 7
N1 24 4 1
N2,3 26 7 2 NS
Stage
85 23- 7
11 19 3 1
IIIA 44 11 2
IIIB 5 1 0 NS
Tumour size (mm)
.20 22 6 2
>20to<40 82 17 7
>40to<60 32 9 0
>60 17 6 1 NS
Histology
Ad 84 23 9
Sq 58 12 1
La 10 2 0
As 1 1 0 0.09
(Ad vs non-Ada)
Differentiation
Well 40 13 3
Moderate 73 18 6
Poor 40 7 1 NS
p53 protein status
p53- 84 21 5
p53 + 31 11 2
p53 ++ 38 6 3 NS
aAd, adenocarcinoma; non-Ad, non-adenocarcinoma, including Sq
(squamous cell carcinoma), La (large-cell carcinoma) and As
(adenosquamous cell carcinoma).
RESULTS
MDM2amplification and p53 mutation
Of the 30 patients tested, only two (7%) showed MDM2 gene
amplification (Figure 2 and Table 1): one had stage IIIA adeno-
carcinoma and another stage I squamous cell carcinoma.
Amplification grade was 5.5-fold in the former and 2.7-fold in the
latter. Both showed MDM2 protein expression by immunohisto-
chemical analysis (strongly positive in the former and weakly
positive in the latter, percentage of positive cells being 90% and
48% respectively). In contrast, ten patients showed MDM2 protein
expression with no evidence ofits gene amplification.
In the present series, 4 (27%) of the 15 patients showed p53
mutations (exon 5, 6, 7 or 8 in each, Table 1) using the PCR-FSSCP
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100 L _ n MDM2 positive (++), n=10
80 MDM2 positive (+), n=38
60 MDM2 negative (-), n=153
40 MDM2 negative vs MDM2 positive (+)
vs MDM2 positive (+, P=0O.163
20 MDM2 negative vs




Figure 3 Post-operative survival curves according to MDM2 protein
expression in 201 NSCLC patients. Overall, among the three groups
(- vs + vs ++), there is no statistical difference in post-operative survival
curves (P= 0.163), but MDM2-positive patients, including those with strong
(++) and weak (+) expression, show marginally better prognosis than
MDM2-negative patients (P= 0.062)
Table 3 P-value from univariate analysis using the log-rank test for 201
NSCLC patients undergoing potentially curative operation
Variables P-value
Gender
Male vs Female 0.260
Age (year)
<60 vs 61< 0.191
T-factor
Ti vs T2 vs T3,4 0.048
N-factor
NO vs Ni vs N2,3 < 0.0001
Stage
vs 11 vs III < 0.0001
Tumour size (mm)
<30 vs 31 < 0.079
Histology
Ad vs non-Ad* 0.752
Differentiation
Well vs moderate vs poor 0.002
p53 protein status
-vs +vs ++ 0.449
-vs +, ++ 0.746
MDM2 protein status
-vs +vs ++ 0.163
- vs +, ++ 0.062
aAd, adenocarcinoma; non-Ad, non-adenocarcinoma, including Sq
(squamous cell carcinoma), La (large-cell carcinoma) and As
(adenosquamous cell carcinoma).
method. Although the two patients with MDM2 gene amplification
and MDM2 protein expression also showed p53 protein accumula-
tion, no p53 mutation was observed.
Association between MDM2 protein expression and
clinicopathological parameters
Of the 201 patients tested, a total of 48 (24%) showed positive
immunostaining for MDM2 protein within the tumour tissue: ten
(5%) were in the strongly positive group and 38 (19%) were in the
weakly positive group. The median percentage ofMDM2-positive
cells was 75% (mean ± s.d. 78 ± 17%, range 55-99%) in the
former and 30% (mean ± s.d. 28 ± 7%, range 11-48%) in the latter.
Table 4 Multivariate analysis of Cox's proportional hazards model in 110
p53-negative patients
Variables Coefficient s.e. P2 Pvalue
T-factor
T1,2 vs T3,4 0.228 0.219 1.085 0.299
N-factor
No vs N1,2,3 0.955 0.204 21.990 <0.0001
Differentiation
Well, moderate vs poor 1.717 0.264 0.423 0.517
MDM2 protein
-vs +, ++ -0.568 0.269 4.477 0.037
In comparison with the non-adenocarcinoma type, including squa-
mous cell carcinoma, large-cell carcinoma and adenosquamous cell
carcinoma, adenocarcinoma type marginally frequently showed
MDM2 protein expression (P = 0.09). However, MDM2 protein
status was not associated with the representative clinicopatholog-
ical parameters, such as T-classification (T-factor), nodal involve-
ment (N-factor), stage, tumour size or differentiation (Table 2).
p53 protein accumulation was seen in a total of 91 patients
(45%): 47 (23%) patients showed strongly positive immunoreac-
tivity for p53 protein (median percentage of positive cells 89%,
mean ± s.d. 88 ± 5%, range 55-100%) and 44 (22%) showed weak
positivity (median percentage of positive cells 28%, mean ± s.d.
33 ± 8%, range 13-49%). There was no association between
MDM2 protein expression and p53 protein accumulation status in
the present series (Table 2). The immunohistochemical distribu-
tion ofpositive cells in the tumour tissue ofboth MDM2- and p53-
positive patients was diverse: some patients showed an almost
similar pattern ofdistribution, while others showed mosaic pattern
of MDM2 protein expression and p53 protein accumulation in
the tissue.
Post-operative prognosis
Decending on MDM2 protein expression status, post-operative
overall survival was analysed for 201 patients (Figure 3). Overall,
there was no statistically significant difference in prognosis among
the three groups (P = 0.163), but MDM2-positive patients,
including those strongly and weakly positive, showed slightly
better prognosis than MDM2-negative patients (P = 0.062). In
addition to MDM-2 protein status, T-factor, N-factor, stage,
tumour size and differentiation were also significantly or margin-
ally significantly associated with prognosis (Table 3). p53 protein
status showed no influence on prognosis in the present series.
Considering a biophysiological function of MDM2 and p53
proteins (Olson et al, 1993; Haines et al, 1994), survival was
separately analysed according to p53 protein status. In the p53-
negative group (110 patients), MDM2-positive patients, including
those strongly and weakly positive, showed a significantly more
favourable prognosis than MDM2-negative patients (Figure 4A,
P = 0.039). In particular, even among the p53-negative group with
stage I disease (64 patients), a similar result was obtained (Figure
4B, P = 0.049). In a multivariate analysis of the p53-negative
group (Table 4), the P-value of MDM2 protein expression was
significant for survival (P = 0.037), in addition to N-factor.
However, among the p53-positive group (91 patients), there was
no difference in the post-operative survival curve with the MDM2
protein status (Figure 4C, P = 0.556).
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Figure 4 Post-operative survival curves according to MDM2 protein
expression among p53-negative group (A), p53-negative group with stage
disease (B) and among p53-positive group (C). In the p53-negative group
(110 patients), the MDM2-positive patients (++ and +) showed significantly
more favourable prognosis than the MDM2-negative patients (A, P = 0.039),
even in the p53-negative group with stage disease (64 patients)
(B, P = 0.049). In contrast, in the p53-positive group (91 patients), there
was no difference in post-operative survival curves (C, P = 0.556)
DISCUSSION
MDM2 gene amplification has been described in several types of
human sarcomas (Leach et al, 1993; Florenes et al, 1994; Bueso-
Ramos et al, 1995; Nakayama et al, 1995), including 15-36% of
soft tissue sarcomas and 10-15% ofosteosarcomas. Similarly, this
amplification has been detected in 8-10% of brain tumours
(Reifenberger et al, 1993). MDM2 gene amplification has also
been reported in human cancers, such as breast cancer, in which its
incidence is 4-13% of the primary tumours (Marchetti et al,
1995b; McCann et al, 1995), and oesophageal cancer, in which the
incidence is as high as 18% (Shibagaki et al, 1995); but overall in
other cancers, including urinary bladder tumours (Lianes et al,
1994), cervical cancers (Kessis et al, 1993; Ikenberg et al, 1995),
head and neck tumours (Waber et al, 1993), some paediatric
tumours (Waber et al, 1993) and urothelial cancers (Habuchi et al,
1994), this event is now considered to be rather infrequent. In the
NSCLC cases studied here, its incidence was only 7% (2 of 30
patients tested), compatible with that (6%) reported by Marchetti
et al (1995a), and, in addition, its amplification grade was rela-
tively low (5.5-fold and 2.7-fold) in comparison with the other
tumours, indicating that amplification of this oncogene in this
disease may also be a relatively infrequent event through tumori-
genesis and tumour development. Interestingly, Marchetti et al
(1995a) emphasized that MDM2 gene amplification was observed
only in patients with adenocarcinoma but, in the present study,
one patient with squamous cell carcinoma showed MDM2 gene
amplification.
In immunohistochemical studies using monoclonal anti-MDM2
protein antibody, the incidence of MDM2 immunohistochemical
(over)expression in human cancers has been reported to be 30% in
bladder cancers (Lianes et al, 1994), 20% in colorectal cancers
(Ofner et al, 1995), 3% in ovarian cancers (Foulkes et al, 1995),
40% in oral carcinoma (Matsumura et al, 1996) and 22-41% in
breast cancers (Marchetti et al, 1995b; McCann et al, 1995). In
NSCLC, whereas Marchetti et al (1995a) reported that MDM2
oncogene product expression was detected immunohistochemi-
cally only in three (6%) patients with gene amplification, it was
detected in the present study in 24% ofpatients, independently of
MDM2 gene amplification status. This difference in incidence
reported between Marchetti et al (1995a) and ourselves is probably
caused by the use of frozen sections in the former study, whereas
paraffin sections, possibly larger in size, were used in the present
study. In addition, the criteria for the positivity ofimmunostaining
may have been another related factor. Thus, when considering
together our findings on NSCLC, we believe that its expression
(in contrast to its gene amplification) is not a rare, but a more
common, event in human cancer tissues.
Although Marchetti et al (1995a) reported that MDM2 protein
was not detected in patients with squamous cell carcinoma, 13
patients in this study, including 12 with weak and one with strong
expression, expressed its protein. Recently, Matsumura et al
(1996) reported that MDM2 protein was observed immunohisto-
chemically in 40% of oral squamous cell carcinomas. Therefore,
considering these results together, MDM2 gene productexpression
does occur in adenocarcinoma type in NSCLC, slightly frequently.
The relationship between MDM2 gene amplification and
increased expression of the product appears to be complicated and
is not completely understood. In fact, in several unique cases, the
gene wasamplified inthe absence ofincreasedexpression (McCann
et al, 1995). Although we did not examine the MDM2 gene mRNA
levels in NSCLC, one case exhibiting gene amplification (case
no. 3) showed strong expression of its product (percentage ofposi-
tive cells 90%) and another (case no. 24) showed weak expression
(percentage of positive cells 48%). Marchetti et al (1995a) also
reported that all of the patients in their study with MDM2 gene
amplification did not show strong expression ofits protein.
In the present study, there was no significant association
between MDM2 expression and tumour-staged parameters (Table
2) and, even in regard to MDM2 gene amplification, one case was
in stage I and another in stage IIIA. There was also no such associ-
ation in the three patients with positive amplification and overex-
pression described by Marchetti et al (1995a). In addition, MDM2
protein status did not appear to be associated with p53 protein
accumulation status (Table 2), and there was no definite distribu-
tion of positive cells in the tumour tissue of both MDM2- and
p53-positive patients. Thus, the combination of MDM2 and p53
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abnormalities in NSCLC may be not so simple. However, only in
the two patients with MDM2 amplification, no p53 gene mutation
was detected in spite of strongly positive p53 protein accumula-
tion; this observation is compatible with that of Marchetti et al
(1995a). Considering that the antibody recognizes both the wild-
type and the mutant forms of p53 protein, it is possible that
immunohistochemically detected protein in such patients is wild-
type p53, which may be stabilized and accumulated by MDM2
protein expression (Keleti et al, 1996).
The prognostic value of MDM2 protein expression is observed
only among p53-negative patients, but not among p53-positive
patients. The observation that MDM2-positive patients showed
marginally better prognosis than MDM2-negative patients, on the
whole, reflects the findings among p53-negative patients. Thus, it
is concluded that MDM2 protein status is a useful prognostic
marker only in such patients. Considering a biophysiological func-
tion of MDM2 and p53 proteins (Olson et al, 1993; Haines et al,
1994), mutant-type p53 itself may have lost its p53 function,
leading to the speculation that MDM2 abnormalities have little or
no effect on the p53-mediated pathway. The findings observed
among p53-positive patients in this study support this hypothesis.
In contrast, we had hypothesized that MDM2 abnormalities are
an alternative mechanism, escaping from p53-regulated growth
control in wild-type p53 tumours in the same fashion as in mutant-
p53 tumours, but the present findings obtained in NSCLCs appear
to be rather paradoxical.
The reason for the present clinical outcome among the p53-
negative patients is unknown. In this respect, it was recently
reported that the MDM2 gene encodes a number of alternatively
spliced mRNAs that give rise to proteins ranging in size from
40 kDa to 90 kDa. Several investigators have described not only a
p90 protein, the original form, but also the representative forms,
p57-58, p74, p76 and p85 proteins as the MDM2 gene products in
various types of tumours (Olson et al, 1993; Haines et al, 1994;
Landers et al, 1994; Bueso-Ramos et al, 1995; Gudas et al, 1995).
In particular, it is noteworthy that the variant forms p74 and p76,
lacking the N-terminal protein domain of p90 protein, do not
inhibit p53 protein (Olson et al, 1993; Haines et al, 1994). The
antibody IF2, used in the present study, enables detection of such
forms as p90, p74, p76 and p57-58 (Haines et al, 1994; Gudas
et al, 1995). Therefore, some immunohistochemically detected
MDM2-positive patients may have been included as showing a
different function ofvariant MDM2 protein, e.g. p74 or p75, from
the original MDM2 protein, p90. Secondly, p53 abnormalities
examined by immunohistochemistry are not always consistent
with those examined by analysis of its gene. In fact, several
patients even with strongly positive p53 accumulation showed no
p53 mutation by the PCR-FSSCP method (Table 1). Conversely, it
is possible that some p53-negative patients may have been
included as those with some p53 abnormalities at the gene level.
The presentprognostic analysis was firmly based on immunohisto-
chemistry for tumour phenotype and, therefore, further study is
needed to elucidate the mechanism underlying the apparently
contradictory effects ofMDM2 protein on prognosis.
In other tumours, the prognostic value of MDM2 abnormalities
remains controversial. In breast cancers, MDM2 overexpression is
strongly associated with oestrogen receptor expression, suggesting
that MDM2 expression status may also be a favourable prognostic
factor (Sheikh et al, 1993; Takami et al, 1994; Marchetti et al,
1995b; McCann et al, 1995; Gudas et al, 1995). In bladder cancer,
Lianes et al (1994) reported that MDM2 overexpression was
observed in patients with relatively early-staged and low-grade
tumours, suggesting that MDM2 overexpression may be an early
event or possibly a favourable factor associated with low-grade
malignancy, although there have been no reports clearly describing
its association with prognosis. On the other hand, in oesophageal
cancer, MDM2 gene amplification has been described as being a
rather unfavourable prognostic factor (Schibagaki et al, 1995).
MDM2 overexpression in leukaemias also appears to be associated
with unfavourable chromosomal abnormalities (Bueso-Ramos et
al, 1993). Thus, the influence of MDM2 gene abnormalities on
tumour malignancy may appear to be different when studied with
tumour tissues. Further study is needed considering p53 abnormal-
ities in these tumours to determine the prognostic value ofMDM2
abnormalities.
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